CD274 and non-small cell lung carcinoma: Overall, the combination of cemiplimab with chemotherapy improved OS, PFS, and overall response rate (ORR) in patients with advanced NSCLC, irrespective of histological subtype and PD-L1 expression levels, but with a higher incidence of TRAEs [63].